Core Viewpoint - Quantum BioPharma Ltd. has entered into a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis patients [1][2]. Group 1: Clinical Study Details - The clinical study is titled "Preliminary Evaluation of [18F]3F4AP PET as a potential tool to monitor non-immunomodulatory drugs in multiple sclerosis" and is led by Dr. Pedro Brugarolas from MGH [2]. - The study will involve serial [18F]3F4AP PET scans alongside MRI scans in patients with both progressive and relapsing-remitting forms of MS [2]. - Previous studies indicated that [18F]3F4AP is highly sensitive to demyelinated lesions, suggesting its potential as a biomarker for monitoring demyelination changes in response to treatments [2]. Group 2: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of the UNBUZZD™ product, and will receive a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [4]. - The collaboration with MGH is seen as relevant to the Lucid-MS clinical development program, which aims to protect the myelin sheath in MS [3].
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis